Exclusive: Intel's new CEO plots overhaul of manufacturing and AI operations
Intel's incoming CEO Lip-Bu Tan has considered significant changes to its chip manufacturing methods and artificial ...
Business Insider5d
ViiV announces new study data showing zero HIV cases with Apretude
GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as shareholders, announced new data from two ...
Business Insider5d
ViiV Healthcare announces data from EMBRACE Phase IIb study
ViiV Healthcare, majority owned by GSK (GSK), with Pfizer (PFE) (PE) and Shionogi as shareholders, announced findings from the company’s EMBRACE phase IIb study. The study found that N6LS, given ...
News Medical5d
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.
Yahoo Finance5d
ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
LONDON, March 12, 2025--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two ...
PharmiWeb6d
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
These results were presented today at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, U.S. Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV ...
Business Wire5d
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s ...
Benzinga.com5d
GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study
Updated daily— discover the market’s highest-rated stocks now. ViiV Healthcare announced Wednesday the latest findings from its EMBRACE phase 2b study. The study found that N6LS (VH3810109 or ...
Morningstar5d
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
Based on the favourable results seen in the trial, ViiV Healthcare will be progressing a six-month IV formulation of VH109 in combination with CAB LA for further evaluation in an EMBRACE part two ...
PharmiWeb5d
ViiV Healthcare announces new implementation study…
London, 12 March 2025 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies ...
Benzinga.com5d
1GSK, PFE : GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In...
Updated daily— discover the market’s highest-rated stocks now. ViiV Healthcare announced Wednesday the latest findings from its EMBRACE phase 2b study. The study found that N6LS (VH3810109 or ...